Loading clinical trials...
Loading clinical trials...
An Open-Label Expanded Access Trial for Bendamustine HCl in Patients With Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia
Conditions
Interventions
Bendamustine at a dose of 100 mg/m2
Bendamustine at a dose of 120 mg/m2
Locations
16
Canada
CA015
Calgary, Alberta, Canada
CA014
Edmonton, Alberta, Canada
CA016
Kelowna, British Columbia, Canada
CA011
Vancouver, British Columbia, Canada
CA013
Victoria, British Columbia, Canada
CA012
Winnipeg, Manitoba, Canada
Start Date
March 1, 2012
Primary Completion Date
June 1, 2013
Completion Date
June 1, 2013
Last Updated
August 14, 2017
NCT06846671
NCT07218341
NCT06548152
NCT07030400
NCT07277231
NCT05006716
Lead Sponsor
Lundbeck Canada Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions